吕祁

副教授

E-mail：qilv@njucm.edu.cn

主要研究方向：

溃疡性结肠炎与结直肠癌的中药干预机制

个人简介

[1] Lv Q^#, Zhang Y^#, Gao W^#, Wang J, Hu Y, Yang H, Xie Y, Lv Y, Zhang H, Wu D^*, Hu L^*, Wang J^*. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer. Pharmacol Res. 2024; 202: 107126.

[2]Lv Q^#, W Juan^#, Yang H^#, Chen X, Zhang Y, Ji G, Hu L^*, Zhang Y^*. Didymin ameliorates ulcerative colitis-associated secondary liver damage by facilitating Notch1 degradation. Phytomedicine. 2024; Doi: 10.1016/j.phymed.2024.155561.

[3]Lv Q^#, Yang H^#, Wang D^#, Zhou H, Wang J, Zhang Y, Wu D, Xie Y, Lv Y, Hu L^*, Wang J^*. Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profile and Superior Efficacy in Colorectal Cancer Immunotherapy. J Med Chem. 2024; Doi: 10.1021/acs.jmedchem.4c00508.

[4] Wang P^#, Yang H^#, Lin W^#, Zhou J, Liu Y, Ma L, Li M, Hu Y, Yu C, Zhang Y, Lv Q^*, Liu J^*, Hu L^*. Discovery of novel sesquiterpene lactone derivatives as potent PKM2 activators for the treatment of ulcerative colitis. J Med Chem. 2023; 66 (8): 5500-5523.

[5] Lv Q^#, Xing Y^#, Liu J, Dong D, Liu Y, Qiao H, Zhang Y^*, Hu L^*. Lonicerin targets EZH2 to alleviate ulcerative colitis by autophagy-mediated NLRP3 inflammasome inactivation. Acta Pharm Sin B. 2021; 11 (9): 2880-2899.

[6] Lv Q^#, Xing Y^#, Liu Y, Chen Q, Xu J, Hu L^*, Zhang Y^*. Didymin switches M1-like toward M2-like macrophage to ameliorate ulcerative colitis via fatty acid oxidation. Pharmacol Res. 2021; 169: 105613.

[7] Lv Q^#, Xing Y, Dong D, Hu Y, Chen Q, Zhai L, Hu L^*, Zhang Y^*. Costunolide ameliorates colitis via specific inhibition of HIF1α/glycolysis-mediated Th17 differentiation. Int Immunopharmacol. 2021; 97: 107688.

[8] Lv Q^#, Pan X^#, Wang D^#, Rong Q, Ma B, Xie X, Zhang Y, Wang J^*, Hu L^*. Discovery of (Z)-1-(3-((1H-Pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)-3-(isoxazol-3-yl)urea derivatives as novel and orally highly effective CSF-1R inhibitors for potential colorectal cancer immunotherapy. J Med Chem. 2021; 64 (23): 17184-17208.

[9] Zhuang H^#, Lv Q^#, Zhong C, Cui Y, He L, Zhang C, Yu J^*. Tiliroside Ameliorates Ulcerative Colitis by Restoring the M1/M2 Macrophage Balance via the HIF-1α/glycolysis Pathway. Front Immunol. 2021; 12: 649463.

[10] Lv Q^#, Wang K^#, Qiao S, Yang L, Xin Y, Dai Y^*, Wei Z^*. Norisoboldine, a natural AhR agonist, promotes Treg differentiation and attenuates colitis via targeting glycolysis and subsequent NAD+/SIRT1/SUV39H1/H3K9me3 signaling pathway. Cell Death Dis. 2018; 9 (3): 258.

科研项目

[1] 国家自然科学基金青年项目, 81903885, 基于Th17/Treg平衡探索木香烃内酯抗溃疡性结肠炎的作用机制, 2020/01/01-2022/12/31, 主持, 20万元,

[2]南京中医药大学自然科学基金青年项目，NZY81903885, 基于Th17/Treg平衡探索木香烃内酯抗溃疡性结肠炎的作用机制, 2020/01/01-2022/12/31, 主持, 20万元

[3] 国家自然科学基金面上项目, 82274220, 鲜用蒲公英拮抗细菌外毒素感染的物质微观结构基础及其关联作用机制, 2023/01/01-2026/12/31, 52万元, 参与

[4] 国家自然科学基金重点项目, U2102201, 强活性、高选择性的NLRP3炎症小体活化抑制剂去氢木香烃内酯的作用机制及其构效关系研究, 2022/01/01-2025/12/31, 参与, 23万元

[5] 国家自然科学基金面上项目, 82073719, 基于Th17/Treg平衡调节作用的木香烃内酯抗溃疡性结肠炎药构效关系研究, 2021/01/01-2024/12/31, 参与, 55万元

代表性论文